#United States #Anixa Biosciences #San Jose #Breast Cancer #Cancer Vaccines

Anixa Biosciences Set to Present at Water Tower Research Fireside Chat

On December 15, 2025, Anixa Biosciences, Inc., a clinical-stage biotechnology company known for its innovative approaches to cancer treatment and prevention, will participate in a Fireside Chat hosted by Water Tower Research. Dr. Amit Kumar, the company’s Chairman and CEO, will lead the discussion, which is set to take place at 1:00 PM ET.

The Fireside Chat promises to delve into critical topics surrounding Anixa’s recent developments. Notably, Dr. Kumar will discuss findings from the company’s Phase 1 trial of a breast cancer vaccine, which will be publicly presented just a few days prior at the San Antonio Breast Cancer Symposium on December 11, 2025. The results from this trial are highly anticipated, as they may provide pivotal insights into the efficacy of the vaccine.

Additionally, the discussion will address the implications of utilizing a retired protein strategy in the development of cancer vaccines—a method that Anixa brings to the forefront of its research. Understanding this approach could be essential for advancing future innovation in cancer treatments. Dr. Kumar will also outline next steps for vaccine development, indicating how Anixa plans to expand its research and clinical trials based on recent findings and ongoing projects.

The upcoming Fireside Chat is an open-access event, making it a unique opportunity for investors and interested parties to engage directly with the company’s leadership. Participation is straightforward, as potential attendees are encouraged to register through Water Tower Research’s platform.

About Anixa Biosciences

Anixa Biosciences focuses on developing groundbreaking immunotherapy treatments, primarily for cancers with significant unmet medical needs. Noteworthy among their initiatives is a collaboration with Moffitt Cancer Center, where they are advancing an ovarian cancer immunotherapy that utilizes a novel CAR-T technology. This innovative approach employs chimeric endocrine receptor-T cell (CER-T) technology, setting it apart from traditional methodologies by enabling direct targeting of tumor cells through the natural ligand of the FSHR receptor.

In addition to ovarian cancer initiatives, Anixa is advancing a portfolio of vaccine candidates, which are being developed in collaboration with the Cleveland Clinic. These candidates aim to provide effective prevention and treatment options for breast cancer, ovarian cancer, and other challenging malignancies, including lung, colon, and prostate cancers. The focus on “retired” proteins that are associated with these cancers reflects a promising avenue in immunotherapy, as these proteins seem to be prevalent in certain cancerous cells.

The commitment to partner with esteemed research institutions like the Cleveland Clinic underscores Anixa’s strategy of leveraging top-tier academic research to propel their pipeline forward. This partnership grants Anixa exclusive licensing rights to pivotal vaccine technologies, while also establishing a revenue-sharing agreement regarding commercialization—benefiting both organizations.

With ongoing trials and forward-looking approaches, Anixa Biosciences continues to push the boundaries of what is possible in cancer treatment and prevention. For those interested in learning more about the company’s developments and contributions to biotechnology, more information is accessible through their official website and social media platforms, including LinkedIn and Facebook.

Conclusion

Attending the Water Tower Research Fireside Chat will undoubtedly offer valuable insights into Anixa Biosciences’ research strategies and the future of cancer treatment initiated by their innovative vaccine trials. With the potential to reshape the landscape of oncology, the company's upcoming discussions are essential for investors and stakeholders keen on understanding the trajectory of cancer therapies.